Related Experiment Video
Updated: Jul 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Lung cancer]
Masahiro Tsuboi1, Harubumi Kato
1Dept. of General Thoracic Surgery, Tokyo Medical University, Nishi-shinjyuku, Tokyo, Japan.
Abstract:
Although surgery offers the best chance of cure for patients with early stage (I-resectable III A) non-small cell lung cancer (NSCLC), the overall 5-year survival rate is modest, and systematic improvements are needed. In the 1990s, two small prospective randomized phase III trials demonstrated striking results with neo-adjuvant chemotherapy and therefore several randomized trials were performed. However, there was no statistical significant trial among them. The recent systematic meta-analysis based on 8 trials revealed hazard ratio was 0.88 (95%CI: 0.76-1.01), although these data suggested a 12% relative benefit with the neoadjuvant chemotherapy, equivalent to an absolute improvement in survival of 5% at 5 years. For patients with stage N2-III A NSCLC, US intergroup trial (INT0139) also demonstrated there was no statistical difference between chemoradiotherapy following surgery and chemoradiotherapy on overall survival. At present, there is no scientific evidence of the neoadjuvant strategy for early stage NSCLC in practice. This invasive treatment is still investigational and should be done as the clinical trial base.
Related Concept Videos
Other Pulmonary Disorders
lncRNA - Long Non-coding RNAs
Cancer Prevention
Some...
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
Cancer